Page 57 - Read Online

Page 247 Huang et al. J Transl Genet Genom 2021;5:240-9 https://dx.doi.org/10.20517/jtgg.2021.14

[37]
breast cancer based on an in vitro study .

CONCLUSION
HSD3B1(1245C) has been found to be associated with ADT resistance and poorer prognosis. Its association
with next-generation hormone therapy is still unclear (i.e., abiraterone). Very few commercial genetic
profiling products have included this variant in routine testing. However, its clinical impact as well as its
high cost-effectiveness (single variant testing is usually inexpensive) should not be underestimated. Based
on the review of the current evidence, clinicians should consider a more aggressive treatment or follow-up
strategy for patients with HSD3B1(1245C) variants who are undergoing ADT.

DECLARATIONS
Authors’ contributions
Conception and design: Na R, Huang D, Huang J
Literature review: Huang J, Huang D
Manuscript writing: Na R, Huang D, Huang J
All authors contributed to the article and approved the final version.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for
patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials
Working Group. J Clin Oncol 2008;26:1148-59. DOI PubMed
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum
phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40. DOI PubMed
3. Pagliarulo V. Androgen deprivation therapy for prostate cancer. Adv Exp Med Biol 2018;1096:1-30. DOI PubMed
4. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of
resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76-85. DOI PubMed PMC
5. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. Annu Rev Med 2019;70:479-99. DOI PubMed PMC
6. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation
resistance in prostate cancer at the molecular level. Eur Urol 2015;67:470-9. DOI PubMed PMC
7. Sharifi N. Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol 2013;27:708-14. DOI PubMed
PMC
8. Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant
prostate cancer in the era of precision oncology. Eur Urol 2019;75:88-99. DOI PubMed
9. Davis ID, Martin AJ, Stockler MR, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate